Betterbrand Positions BetterLungs Supplement for Respiratory Support Amid 2026 Wildfire Season

Betterbrand's BetterLungs supplement is being positioned as a consumer-facing respiratory support product as wildfire smoke drives air quality indices past "Unhealthy" thresholds across California, Texas, Colorado, and the Pacific Northwest in the 2026 season. For industry observers, the product's third-party testing posture and ingredient selection reflect a broader consumer health trend toward OTC-adjacent supplement formulations targeting pollution-related respiratory stress.

The company, founded in 2019 by Dr. Chris Jackson, PharmD, reports a customer base exceeding one million. BetterLungs combines seven ingredients — including N-acetyl cysteine (NAC), mullein leaf, elderberry, and reishi mushroom — selected for roles in mucolytic activity, antioxidant defense, and immune modulation. NAC's mechanism is well-documented in the literature: it thins mucus secretions and serves as a glutathione precursor, supporting cellular defense against oxidative stress from fine particulate matter.

Purity and potency testing is conducted by Eurofins Scientific, a recognized third-party laboratory. The use of an accredited external testing partner is consistent with quality expectations in the supplement sector, though BetterLungs is classified as a dietary supplement and is not subject to 21 CFR Part 211 drug GMP requirements or FDA pre-market approval.

The EPA characterizes wildfire smoke as a complex mixture of gases and fine particles capable of exacerbating asthma, COPD, and cardiovascular conditions. The 2026 season has produced sustained AQI exceedances in major metropolitan areas, creating visible consumer demand for respiratory support products. Long-term particulate exposure has been associated with lasting pulmonary damage even in otherwise healthy individuals, a dynamic that extends the commercial window beyond acute smoke events.

The product is distributed through Amazon and the company's direct-to-consumer site. No clinical trial data specific to BetterLungs was cited in the announcement; efficacy claims reference ingredient-level published research rather than finished-product studies.

As wildfire seasons lengthen and consumer awareness of air quality risk grows, the supplement sector's capacity to substantiate structure-function claims with finished-product evidence will increasingly determine regulatory and market durability for products in this category.

Source: Betterbrand via GlobeNewswire, June 15, 2026.